CD274 and cancer: For example, combined therapy with nivolumab and ipilimumab not only has been shown to lead to higher overall survival rates in patients with cancer with varying programmed cell death-ligand 1 (PD-L1) expression levels but also increases the incidence of grade 3 or 4 irAEs (around 33%) [4].